Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
BMC Cardiovascular Disorders|December 5, 2021
Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004-2016Esben Skov Jensen, Kevin Kris Warnakula Olesen, Christine Gyldenkerne, et al.
American Heart Journal|May 6, 2019
Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomized SORT OUT IX trialLisette Okkels Jensen, Michael Maeng, Bent Raungaard, et al.
The American Journal of Cardiology|November 4, 2018
Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial FibrillationKevin Kris Warnakula Olesen, Kamilla Steensig, Morten Madsen, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 5, 2022
Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trialJulia Ellert-Gregersen, Lisette Okkels Jensen, Lars Jakobsen, et al.
Diabetes & Vascular Disease Research|July 30, 2020
Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart RegistryChristine Gyldenkerne, Kevin Kw Olesen, Pernille G Thrane, et al.
The Lancet Regional Health. Europe|February 11, 2022
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western DenmarkPernille Gro Thrane, Kevin Kris Warnakula Olesen, Morten Würtz, et al.
Coronary Artery Disease|April 10, 2020
Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trialJulia Ellert, Michael Maeng, Bent Raungaard, et al.
European Journal of Clinical Investigation|August 15, 2017
Coronary artery disease and risk of adverse cardiac events and strokeKevin Kris Warnakula Olesen, Morten Madsen, Gregory Y H Lip, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 23, 2019
Characterisation of lesions undergoing ischaemia-driven revascularisation after complete revascularisation versus culprit lesion only in patients with STEMI and multivessel disease: a DANAMI-3-PRIMULTI substudyOle De Backer, Jacob Lønborg, Steffen Helqvist, et al.
American Heart Journal|May 29, 2018
Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trialLars Jakobsen, Evald H Christiansen, Michael Maeng, et al.
Pageof 6